![N-[1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-oxopyrimidin-4-yl]-2-methylpropanamide chemical structure N-[1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-oxopyrimidin-4-yl]-2-methylpropanamide (CAS: 110522-75-3) - Chemical Structure and Molecular Formula](/static/img/prod_pic/FT-0770516.png) 
                                        ![N-[1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-oxopyrimidin-4-yl]-2-methylpropanamide chemical structure thumbnail N-[1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-oxopyrimidin-4-yl]-2-methylpropanamide (CAS: 110522-75-3) - Chemical Structure Thumbnail](/static/img/prod_pic/FT-0770516.png) 
                                        N-[1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-oxopyrimidin-4-yl]-2-methylpropanamide
Catalog No: FT-0770516
CAS No: 110522-75-3
- Chemical Name: N-[1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-oxopyrimidin-4-yl]-2-methylpropanamide
- Molecular Formula: C13H19N3O5
- Molecular Weight: 297.31
- InChI Key: PDTIVAGPIHEWDX-IQJOONFLSA-N
- InChI: InChI=1S/C13H19N3O5/c1-7(2)12(19)14-10-3-4-16(13(20)15-10)11-5-8(18)9(6-17)21-11/h3-4,7-9,11,17-18H,5-6H2,1-2H3,(H,14,15,19,20)/t8-,9+,11+/m0/s1
| Assay | Pack Size | Price | Stock | Action | 
|---|---|---|---|---|
| 98% | 1g | N/A | N/A | |
| 98% | 5g | N/A | N/A | |
| 98% | Bulk Quantity | N/A | N/A | 
| Bolling_Point: | N/A | 
|---|---|
| CAS: | 110522-75-3 | 
| MF: | C13H19N3O5 | 
| Density: | 1.49g/cm3 | 
| Melting_Point: | N/A | 
| Product_Name: | ibu-deoxycytidine | 
| Flash_Point: | N/A | 
| FW: | 297.30700 | 
| MF: | C13H19N3O5 | 
|---|---|
| Density: | 1.49g/cm3 | 
| Exact_Mass: | 297.13200 | 
| FW: | 297.30700 | 
| Refractive_Index: | 1.641 | 
| PSA: | 113.68000 | 
 
                             
                                                     
                                                     
                                                     
                                                     
                                                     
                                                     
                                                     
                                                     
                                                    